Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Human papillomavirus vaccine TA-CIN - Cancer Research Technology

Next Previous
Drug Profile

Human papillomavirus vaccine TA-CIN - Cancer Research Technology

Alternative Names: TA-CIN; Therapeutic HPV vaccine - Cancer Research Technology

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xenova Group
  • Developer Celtic Pharma
  • Class Cancer vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Human papillomavirus infections

Highest Development Phases

  • Phase II Vulvar intraepithelial neoplasia
  • No development reported Cervical cancer; Cervical dysplasia

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for phase-I development in Cervical-cancer(Adjuvant therapy) in USA (Parenteral)
  • 31 Jan 2025 PapiVax completes a phase I trial in Cervical cancer (Adjuvant therapy) in USA (Parenteral) (NCT02405221)
  • 04 Apr 2019 Phase-I clinical trials in Cervical cancer (Adjuvant therapy) in USA (Parenteral) (NCT02405221)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top